

=> d his

(FILE 'HOME' ENTERED AT 13:45:13 ON 01 MAY 2003)

FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 13:45:32 ON 01 MAY 2003

L1	8366 S (MOUSE OR MICE) (10W) (WEIGHT OR WEIGH)
L2	468 S. L1 AND (WEIGHT OR WEIGH) (15W)MG?
L3	344 DUP REM L2 (124 DUPLICATES REMOVED)

L15 ANSWER 10 OF 10 WPIDS (C) 2003 THOMSON DERWENT

AN 1994-279394 [34] WPIDS

CR 1999-243165 [20]

DNC C1994-127479

TI **Treatment** and prevention of insulin dependent **diabetes**  
- by administering monoclonal antibodies specified for the integrin VLA4  
blocking interactions with VCAM-1 and **fibronectin**.

DC B04 D16

IN BURKLY, L C; BURKLY, L

PA (BIOJ) BIOGEN INC

CYC 22

PI WO 9417828 A2 19940818 (199434)\* 73p

RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

W: AU CA JP NZ US

AU 9462379 A 19940829 (199501)

WO 9417828 A3 19941013 (199534)

EP 682529 A1 19951122 (199551) EN

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

NZ 262615 A 19960227 (199614)

JP 08508719 W 19960917 (199704) 66p

EP 682529 B1 19980107 (199806) EN 37p

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DE 69407758 E 19980212 (199812)

AU 687790 B 19980305 (199820)

ES 2114183 T3 19980516 (199826)

AU 9869846 A 19980723 (199841)

AU 727187 B 20001207 (200103)

ADT WO 9417828 A2 WO 1994-US1456 19940209; AU 9462379 A AU 1994-62379  
19940209, WO 1994-US1456 19940209; WO 9417828 A3 WO 1994-US1456 19940209;  
EP 682529 A1 EP 1994-909584 19940209, WO 1994-US1456 19940209; NZ 262615 A  
NZ 1994-262615 19940209; JP 08508719 W JP 1994-518333 19940209, WO  
1994-US1456 19940209; EP 682529 B1 EP 1994-909584 19940209, WO 1994-US1456  
19940209; DE 69407758 E DE 1994-607758 19940209, EP 1994-909584 19940209,  
WO 1994-US1456 19940209; AU 687790 B AU 1994-62379 19940209; ES 2114183 T3  
EP 1994-909584 19940209; AU 9869846 A Div ex AU 1994-62379 19940209, AU  
1998-69846 19980602; AU 727187 B Div ex AU 1994-62379 19940209, AU  
1998-69846 19980602

FDT AU 9462379 A Based on WO 9417828; EP 682529 A1 Based on WO 9417828; JP  
08508719 W Based on WO 9417828; EP 682529 B1 Based on WO 9417828; DE  
69407758 E Based on EP 682529, Based on WO 9417828; AU 687790 B Previous  
Publ. AU 9462379, Based on WO 9417828; ES 2114183 T3 Based on EP 682529;  
AU 727187 B Div ex AU 687790, Previous Publ. AU 9869846

PRAI US 1993-29330 19930209

AB WO 9417828 A UPAB: 20010116

A method for the prevention of insulin dependent (type 1) diabetes (IDD)  
comprises administering to a prediabetic individual, a composition  
comprising an anti-VLA4 (very late antigen) antibody (Ab).

Also claimed are (1) a method for the **treatment** of  
**diabetes** comprising administering to a mammal with a  
susceptibility to **diabetes**, an Ab, a recombinant Ab, a chimeric  
Ab, fragments of such Abs, a polypeptide or small mol. capable of binding  
to the alpha4 subunit of VLA4 or combinations of any of these, in an amt.  
sufficient to inhibit the onset of diabetes; and (2) a pharmaceutical  
compsn. consisting of a monoclonal Ab recognising VLA4 in a carrier.

Pref. the anti-VLA4 Ab is selected from HP1/2, HP2/1, HP2/4, L25 and  
P4C2. It is esp. humanised HP1/2 or a fragment. Dosage is 0.1-10mg/kg; an  
amt. effective to coat VLA4-positive cells in the peripheral blood for  
1-14 days. This provides a plasma level of Ab of at least 1 ug/ml. The  
compsn. is administered prior to the development of overt diabetes as  
measured by a serum glucose level of less than about 250 mg/dl.

In the method of (1) the Ab/polypeptide is selected from AMb HP1/2

Fab, Fab', F(ab')<sub>2</sub> or F(v) fragments of such an antibody sol. VCAM-1, esp. VCAM 2D-IgG, or fibronectin polypeptides or small mols. that bind to the VCMA-1 or fibronectin binding domain of VLA4. The compsn. pref. comprises several anti-VLA4 MAbs or VLA4-binding fragments. It is administered at a dosage which provides 0.1-10 mg/kg body weight.

USE - The method provides a way of **treating diabetes** by administering a compsn. which binds to the VLA4 antigens on the surface of VLA4-positive cells, including lymphocytes and macrophages. This induces a change in the function of such cells by interferring with interactions between VLA4 antigens and either VCAM-1 or **fibronectin** on the surface of other cells. This in turn results in a prevention of or protection against the incidence of **diabetes**.  
Dwg.0/8

=>

L15 ANSWER 8 OF 10 WPIDS (C) 2003 THOMSON DERWENT  
 AN 1998-120309 [11] WPIDS  
 DNC C1998-039493  
 TI New cyclic peptide compounds - inhibit cell adhesion and may be used in  
 treating asthma, psoriasis, diabetes or rheumatoid  
 arthritis.  
 DC B04  
 IN DUTTA, A; DUTTA, A S  
 PA (ZENE) ZENECA LTD  
 CYC 79  
 PI WO 9749731 A1 19971231 (199811)\* EN 62p  
 RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT  
 SD SE SZ UG ZW  
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE  
 GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW  
 MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN  
 ZW  
 ZA 9705436 A 19980225 (199813) 59p  
 AU 9731027 A 19980114 (199822)  
 NO 9805966 A 19981218 (199914)  
 EP 910582 A1 19990428 (199921) EN  
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 CN 1222918 A 19990714 (199946)  
 NZ 332778 A 20000825 (200049)  
 JP 2000513350 W 20001010 (200053) 72p  
 MX 9810777 A1 19990401 (200055)  
 KR 2000022075 A 20000425 (200105)  
 US 6235711 B1 20010522 (200130)  
 ADT WO 9749731 A1 WO 1997-GB1641 19970618; ZA 9705436 A ZA 1997-5436 19970619;  
 AU 9731027 A AU 1997-31027 19970618; NO 9805966 A WO 1997-GB1641 19970618,  
 NO 1998-5966 19981218; EP 910582 A1 EP 1997-926150 19970618, WO  
 1997-GB1641 19970618; CN 1222918 A CN 1997-195724 19970618; NZ 332778 A NZ  
 1997-332778 19970618, WO 1997-GB1641 19970618; J

d his

(FILE 'HOME' ENTERED AT 09:16:44 ON 01 MAY 2003)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 09:17:03 ON 01 MAY 2003

SEA (SOLUBIL? OR STABIL?) (15W) PEPTIDE

-----  
18 FILE ADISCTI  
5 FILE ADISINSIGHT  
65 FILE AGRICOLA  
23 FILE ANABSTR  
14 FILE AQUASCI  
75 FILE BIOBUSINESS  
7 FILE BIOCOMMERCE  
1632 FILE BIOSIS  
138 FILE BIOTECHABS  
138 FILE BIOTECHDS  
721 FILE BIOTECHNO  
82 FILE CABA  
184 FILE CANCERLIT  
2224 FILE CAPLUS  
30 FILE CEABA-VTB

SEA (STABILITY) (15W) PEPTIDE

-----  
8 FILE ADISCTI  
2 FILE ADISINSIGHT  
25 FILE AGRICOLA  
15 FILE ANABSTR  
2 FILE AQUASCI  
32 FILE BIOBUSINESS  
679 FILE BIOSIS  
59 FILE BIOTECHABS  
59 FILE BIOTECHDS  
296 FILE BIOTECHNO  
36 FILE CABA  
78 FILE CANCERLIT  
1056 FILE CAPLUS  
11 FILE CEABA-VTB  
5 FILE CEN  
6 FILE CONFSCI  
2 FILE CROPB  
1 FILE CROPU  
19 FILE DDFB  
49 FILE DDFU  
1214 FILE DGENE  
19 FILE DRUGB  
3 FILE DRUGNL  
79 FILE DRUGU  
3 FILE DRUGUPDATES  
4 FILE EMBAL  
601 FILE EMBASE  
359 FILE ESBIOWASE  
30 FILE FEDRIP  
21 FILE FROSTI  
31 FILE FSTA  
4 FILE GENBANK  
36 FILE IFIPAT  
50 FILE JICST-EPLUS

1 FILE KOSMET  
 230 FILE LIFESCI  
 481 FILE MEDLINE  
 1 FILE NIOSHTIC  
 7 FILE NTIS  
 184 FILE PASCAL  
 1 FILE PHAR  
 4 FILE PHIN  
 27 FILE PROMT  
 683 FILE SCISEARCH  
 201 FILE TOXCENTER  
 1634 FILE USPATFULL  
 27 FILE USPAT2  
 1 FILE VETB  
 1 FILE VETU  
 101 FILE WPIDS  
 101 FILE WPINDEX

L1 QUE (STABILITY) (15W) PEPTIDE

-----  
 SEA L1 AND (STABILITY) (15W) IN VIVO  
 -----

12 FILE BIOSIS  
 1 FILE BIOTECHABS  
 1 FILE BIOTECHDS  
 8 FILE BIOTECHNO  
 2 FILE CANCERLIT  
 9 FILE CAPLUS  
 3 FILE DDFU  
 1 FILE DGENE  
 4 FILE DRUGU  
 13 FILE EMBASE  
 7 FILE ESBIODBASE  
 1 FILE JICST-EPLUS  
 7 FILE LIFESCI  
 8 FILE MEDLINE  
 5 FILE PASCAL  
 1 FILE PROMT  
 12 FILE SCISEARCH  
 1 FILE TOXCENTER  
 316 FILE USPATFULL  
 6 FILE USPAT2  
 2 FILE WPIDS  
 2 FILE WPINDEX

L2 QUE L1 AND (STABILITY) (15W) IN VIVO

-----  
 FILE 'USPATFULL, EMBASE, BIOSIS, SCISEARCH, CAPLUS, BIOTECHNO, MEDLINE, ESBIODBASE, LIFESCI, USPAT2, PASCAL, DRUGU, CANCERLIT, WPIDS, BIOTECHDS, DGENE, JICST-EPLUS, PROMT, TOXCENTER' ENTERED AT 09:21:02 ON 01 MAY 2003

L3 416 S L1 AND (STABILITY) (15W) IN VIVO

L4 349 DUP REM L3 (67 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 10:03:29 ON 01 MAY 2003

FILE 'USPATFULL' ENTERED AT 10:05:30 ON 01 MAY 2003

L5 77 S (HALF-LIFE OR STABILITY) (10W) IG

L6 21 S L5 AND PEPTIDE (25W) IG

L7 8 S L5 AND PEPTIDE (10W) IG

L8 31 S L5 AND PEPTIDE (10W) ANTIBOD?

L9 231 S L3 AND PEPTIDE (10W) ANTIBOD?

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,

BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,  
CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,  
DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 10:18:20 ON  
01 MAY 2003

SEA IG(10W)STABILITY

-----  
1 FILE BIOBUSINESS  
25 FILE BIOSIS  
0\* FILE BIOTECHABS  
SEA STABILITY(10W)IN VIVO

-----  
16 FILE ADISCTI  
8 FILE ADISINSIGHT  
3 FILE ADISNEWS  
35 FILE AGRICOLA  
5 FILE ANABSTR  
11 FILE AQUASCI  
53 FILE BIOBUSINESS  
2 FILE BIOCOMMERCE  
811 FILE BIOSIS  
0\* FILE BIOTECHABS

=>

L4 ANSWER 310 OF 349 USPATFULL  
AN 97:120596 USPATFULL  
TI Bradykinin antagonist peptides incorporating N-substituted glycines  
IN Goodfellow, Val S., Westminster, CO, United States  
Marathe, Manoj V., Pittsburgh, PA, United States  
Whalley, Eric T., Golden, CO, United States  
Fitzpatrick, Timothy D., Boulder, CO, United States  
Kuhlman, Karen G., Denver, CO, United States  
PA Cortech, Inc., Denver, CO, United States (U.S. corporation)  
PI US 5700779 19971223  
AI US 1996-668100 19960620 (8)  
RLI Continuation of Ser. No. US 1994-208115, filed on 9 Mar 1994, now  
abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Delaney,  
Patrick R.  
LREP Cushman Darby Cushman IP Group of Pillsbury Madison & Sutro LLP  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1740  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention provides bradykinin type peptides containing  
N-substituted glycines, particularly bradykinin antagonist peptides  
useful for the treatment of conditions mediated by bradykinin including  
pain and inflammation.